Celecoxib

A COX- 2 inhibitor

S. A. Andrews, C. K. Wallace, Robert Davis

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Despite toxicities, NSAIDs still play a major role in patients with RA and OA. Researchers have progressed to understanding the differences between the two isozymes inhibited by NSAIDs. This has led to the development of agents that will only inhibit the enzyme (COX-2) responsible for the production of proinflammatory prostaglandins and not the enzymes (COX-1) responsible for the studies demonstrate that celecoxib appears to have a more favorable side effect profile than traditional NSAIDs. However, more information and research is needed to ensure optimal of COX-2 inhibitors.

Original languageEnglish (US)
Pages (from-to)511-524
Number of pages14
JournalAmerican Journal of Managed Care
Volume5
Issue number4
StatePublished - May 10 1999
Externally publishedYes

Fingerprint

Celecoxib
Cyclooxygenase 2 Inhibitors
Non-Steroidal Anti-Inflammatory Agents
Enzymes
Isoenzymes
Prostaglandins
Research Personnel
Research

All Science Journal Classification (ASJC) codes

  • Health Policy

Cite this

Andrews, S. A., Wallace, C. K., & Davis, R. (1999). Celecoxib: A COX- 2 inhibitor. American Journal of Managed Care, 5(4), 511-524.

Celecoxib : A COX- 2 inhibitor. / Andrews, S. A.; Wallace, C. K.; Davis, Robert.

In: American Journal of Managed Care, Vol. 5, No. 4, 10.05.1999, p. 511-524.

Research output: Contribution to journalReview article

Andrews, SA, Wallace, CK & Davis, R 1999, 'Celecoxib: A COX- 2 inhibitor', American Journal of Managed Care, vol. 5, no. 4, pp. 511-524.
Andrews SA, Wallace CK, Davis R. Celecoxib: A COX- 2 inhibitor. American Journal of Managed Care. 1999 May 10;5(4):511-524.
Andrews, S. A. ; Wallace, C. K. ; Davis, Robert. / Celecoxib : A COX- 2 inhibitor. In: American Journal of Managed Care. 1999 ; Vol. 5, No. 4. pp. 511-524.
@article{e9136ba03a224c149cf30c1be05f1fc5,
title = "Celecoxib: A COX- 2 inhibitor",
abstract = "Despite toxicities, NSAIDs still play a major role in patients with RA and OA. Researchers have progressed to understanding the differences between the two isozymes inhibited by NSAIDs. This has led to the development of agents that will only inhibit the enzyme (COX-2) responsible for the production of proinflammatory prostaglandins and not the enzymes (COX-1) responsible for the studies demonstrate that celecoxib appears to have a more favorable side effect profile than traditional NSAIDs. However, more information and research is needed to ensure optimal of COX-2 inhibitors.",
author = "Andrews, {S. A.} and Wallace, {C. K.} and Robert Davis",
year = "1999",
month = "5",
day = "10",
language = "English (US)",
volume = "5",
pages = "511--524",
journal = "American Journal of Managed Care",
issn = "1088-0224",
publisher = "Ascend Media",
number = "4",

}

TY - JOUR

T1 - Celecoxib

T2 - A COX- 2 inhibitor

AU - Andrews, S. A.

AU - Wallace, C. K.

AU - Davis, Robert

PY - 1999/5/10

Y1 - 1999/5/10

N2 - Despite toxicities, NSAIDs still play a major role in patients with RA and OA. Researchers have progressed to understanding the differences between the two isozymes inhibited by NSAIDs. This has led to the development of agents that will only inhibit the enzyme (COX-2) responsible for the production of proinflammatory prostaglandins and not the enzymes (COX-1) responsible for the studies demonstrate that celecoxib appears to have a more favorable side effect profile than traditional NSAIDs. However, more information and research is needed to ensure optimal of COX-2 inhibitors.

AB - Despite toxicities, NSAIDs still play a major role in patients with RA and OA. Researchers have progressed to understanding the differences between the two isozymes inhibited by NSAIDs. This has led to the development of agents that will only inhibit the enzyme (COX-2) responsible for the production of proinflammatory prostaglandins and not the enzymes (COX-1) responsible for the studies demonstrate that celecoxib appears to have a more favorable side effect profile than traditional NSAIDs. However, more information and research is needed to ensure optimal of COX-2 inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=0032929906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032929906&partnerID=8YFLogxK

M3 - Review article

VL - 5

SP - 511

EP - 524

JO - American Journal of Managed Care

JF - American Journal of Managed Care

SN - 1088-0224

IS - 4

ER -